LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To screen for and diagnose a hepatitis C virus (HCV) infection and to monitor treatment of the infection
To learn more about hepatitis C, read the article on Viral Hepatitis.
For screening: when you have risk factors for HCV infection or were born between 1945 and 1965, per 2012 CDC recommendations
For diagnosis: when you may have been exposed to the hepatitis C virus, such as through contact with infected blood, or have symptoms associated with liver disease
A blood sample drawn from a vein in your arm
Hepatitis C (HCV) is a virus that causes an infection of the liver that is characterized by liver inflammation and damage. Hepatitis C tests are a group of tests that are performed to detect, diagnose, and monitor the treatment of a hepatitis C viral infection. The most common test for HCV looks for antibodies in the blood that are produced in response to an HCV infection. Other tests detect the presence of viral RNA, the amount of viral RNA present, or determine the specific subtype of the virus.
Hepatitis C is one of five hepatitis viruses identified so far, including A, B, D, and E, that are known to cause the disease. HCV is spread by exposure to contaminated blood, primarily though the sharing of needles by intravenous drug users, but also by sharing personal items contaminated by blood such as razors, through sex with an infected person, via healthcare occupational exposure, and, less commonly, from mother to baby during childbirth. Before tests for HCV became available in the 1990s, HCV was often transmitted by blood transfusions.
While HCV is not as contagious as hepatitis B, there is currently no vaccine to prevent infection. Hepatitis C infection is a common cause of chronic liver disease in North America. The Centers for Disease Control and Prevention (CDC) estimates that there were approximately 30,500 cases of acute hepatitis C in the U.S. in 2014 and that there are 2.7 to 3.9 million people in the U.S. living with chronic hepatitis C.
Many of those who are infected have no symptoms and are not aware of the condition. The acute HCV infection may cause few to mild nonspecific symptoms, and the chronic infection may simmer quietly for a decade or two before causing sufficient liver damage to affect liver function.
Hepatitis C infections cause increased risk of developing some other serious conditions:
Hepatitis C antibody tests are used to screen individuals for the infection, including, for example, people with no signs or symptoms but with risk factors, people who have symptoms associated with hepatitis or liver disease, or those who have been exposed to the virus.
Since the antibody test can remain positive in most people even if they have cleared the infection, a positive antibody test is followed by a hepatitis C RNA test, which detects genetic material of the virus. A positive result on the RNA test means the virus is present, the infection has not resolved, and the person may require treatment. The hepatitis C genotype test determines which strain of virus is present to help guide treatment.
Healthcare practitioners may also order a liver panel, which is a group of tests that help assess the health of the liver.
Hepatitis C tests are used to screen for and diagnose a hepatitis C virus (HCV) infection, to guide therapy and/or to monitor the treatment of an HCV infection.
An HCV antibody test is used to screen for past exposure and current infection. It detects the presence of antibodies to the virus, indicating exposure to HCV. This test cannot distinguish whether someone has an active or a previous HCV infection. There is some evidence that if the test is "weakly positive," it may be a false positive. The Centers for Disease Control and Prevention (CDC) recommends that all positive antibody tests be followed by an HCV RNA test that detects viral RNA in the blood to determine whether or not the person has an active infection.
The HCV antibody test may be performed as part of an acute viral hepatitis panel to determine which of the most common hepatitis viruses is causing a person's symptoms.
The following tests may be used to diagnose a current infection and to guide and monitor treatment:
The CDC recommends screening for HCV infections with an HCV antibody test when people:
*The blood supply has been monitored in the U.S. since 1992, and any units of blood that test positive for HCV are rejected for use in another person. The current risk of HCV infection from transfused blood is about one case per two million transfused units.
HCV antibody testing may be done when someone has abnormal results on a liver panel, for example, or signs and symptoms associated with hepatitis. In these cases, it may be done as part of an acute hepatitis panel. Most people newly infected with HCV have no symptoms or ones that are so mild that they rarely prompt a person to visit a healthcare provider and get tested for HCV. However, about 10-20% of people may experience signs and symptoms such as fatigue, pain in the abdominal area, decreased appetite, and jaundice.
An HCV RNA test or viral load is ordered as follow-up testing when an antibody test is positive to confirm an active infection. Some laboratories will automatically perform this test if the HCV antibody test is positive.
HCV genotyping is done when a person has been diagnosed with an HCV infection and is often ordered before treatment is started to guide treatment selection.
HCV viral load testing may be ordered at the start of treatment, periodically to monitor response to treatment, and after the completion of treatment to evaluate its effectiveness.
An HCV antibody test is typically reported as "positive" or "negative."
Results of HCV viral load testing are reported as a number if virus is present. If no virus is present or if the amount of virus is too low to detect, the result is often reported as "negative" or "not detected."
Interpretation of the HCV screening and follow-up tests is shown in the table below. In general, if the HCV antibody test is positive, then the individual tested is infected or has likely been infected at some time with hepatitis C. If the HCV RNA test is positive, then the person has a current infection. If no HCV viral RNA is detected, then the person either does not have an active infection or the virus is present in very low numbers.
|HCV Antibody||HCV RNA||HCV Infection|
|Negative||No infection or too early after exposure for the test to be accurate; if suspicion remains high, retesting at a later time may be required.|
|Positive or Indeterminate||Negative||Past infection or no infection (false-positive screen); additional testing if indicated|
|Positive or Weak or Indeterminate||Positive||Current infection|
For monitoring purposes, an HCV viral load (HCV RNA quantitative) can indicate whether or not treatment is effective. A high or increasing viral load may be a sign that treatment is not successful whereas a low, decreasing, or undetectable viral load may imply that the treatment is working.
Successful treatment causes a decrease of 99% or more in viral load soon after starting treatment (as early as 2-4 weeks) and usually leads to undetectable viral load after treatment is completed. According to guidelines from the American Association for the Study of Liver Diseases and the Infectious Disease Society of America, an undetectable viral load in a treated person's blood 12 weeks after the end of the treatment means that the HCV infection has responded to therapy.
The results of the HCV genotype test identifies which strain of HCV the person has and helps guide the selection and the length of treatment. Treatments may differ depending on a variety of factors, including HCV genotype and the health of the person's liver.
HCV antibodies usually do not appear until several months after exposure but will always be present in the later stages of the disease.
About 25% of those with HIV/AIDS also have an HCV co-infection, and their liver disease is likely to progress at an accelerated rate.
Hepatitis C often leads to chronic hepatitis, which can progress to cirrhosis and liver cancer (hepatocellular carcinoma). Early detection of the virus can alert your healthcare provider to follow your liver function more closely than usual and to treat you if you are chronically infected.
Yes. Liver tests such as ALT and AST are used to indicate ongoing liver injury. People who are still infected with hepatitis C virus (HCV) but always have normal AST and ALT probably have very mild liver disease and may not need treatment. Other tests such as albumin, prothrombin time, and bilirubin can also be used; they are typically normal unless the person has developed cirrhosis. Sometimes a liver biopsy may be performed to determine the severity of liver damage.
No. Currently, there is no vaccine available, although efforts are ongoing to develop one.
Yes. A prior infection with HCV does not protect you from another infection; it does not make you immune to HCV. Most people do not have an effective immune response to the virus. Changes that the virus undergoes as it replicates during an infection make it difficult for the body to fight against the initial or subsequent infections.
Yes. There are several drugs that can be used to treat HCV infection. Most commonly, a combination of drugs is used, and new drugs are under development. Before 2000, chronic HCV was curable in only 10% of cases. Now, treatments for HCV can cure over 90% of those detected before late complications occur, but even those with advanced liver disease often respond to treatment. This increases the opportunity to intervene early and prevent HCV-associated deaths.
There is an FDA-approved test kit available for collecting samples to send to a laboratory for testing. Confidential test results are provided over the telephone. You cannot actually perform the test yourself at home.
If you have detectable HCV RNA in your blood, you have the potential to spread the disease to other people. Hepatitis C is spread by exposure to contaminated blood. The most common mechanism of exposure is the sharing of needles or other 'works' used in consuming drugs such as cocaine or heroin. Other routes of transmission include use of contaminated equipment for body piercing and tattooing, occupational exposure of healthcare workers to used needles or other sharp objects, and, less commonly, through sexual activity that results in tissue tears or from mother to baby during childbirth.
Sources Used in Current Review
(2016) American Liver Foundation. Tests to Diagnose Hepatitis C. Available online at http://hepc.liverfoundation.org/diagnosis/who-should-get-tested/testing-for-hep-c/ Accessed August 1, 2016.
(April 2016) Davis, P. et al. Liver Blood Tests. Available online at http://www.medicinenet.com/liver_blood_tests/page4.htm Accessed August 1, 2016.
(March 28, 2016) Dhawan V. Hepatitis C. Medscape Reference. Available online at http://emedicine.medscape.com/article/177792-overview.
(June 2014) Ryan, B. Why Hepatitis C Tests May Give False Results. HEP. Available online at https://www.hepmag.com/article/false-test-result-25760-476718382. Accessed August 1, 2016.
(July 21 2016) Centers for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. Available online at http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. September 2016.
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available online at http://www.hcvguidelines.org. Accessed September 2016.
Sources Used in Previous Reviews
Clinical Chemistry: Principles, Procedures, Correlations. Michael L. Bishop, Janet L. Duben-Engelkirk, Edward P. Fody. Lipincott Williams & Wilkins, 4th Edition.
The Hepatitis Information Network. Diagnostic Tests for Hepatitis C. By David Gretch, MD, PhD. Available online at http://www.hepnet.com/nih/gretch.html.
(Updated 2009 June 9). Hepatitis C FAQs for the Public. CDC [On-line information]. Available online at http://www.cdc.gov/hepatitis/C/cFAQ.htm#overview. Accessed January 2010.
(2009 April). What I need to know about Hepatitis C. National Digestive Diseases Information Clearinghouse [On-line information]. Available online at http://digestive.niddk.nih.gov/ddiseases/pubs/hepc_ez/index.htm. Accessed January 2010.
(Updated 2009 December 16). Hepatitis C: For Patients and the Public. United States Department of Veterans Affairs [On-line information]. Available online at http://www.hepatitis.va.gov/vahep?page=pt-home. Accessed January 2010.
Hillyard, D. and Slev, P. (Updated 2009 November). Hepatitis C Virus – HCV. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/HCV.html?client_ID=LTD. Accessed January 2010.
Mayo Clinic Staff (2009 September 12). Hepatitis C. MayoClinic.com [On-line information]. Available online at http://www.mayoclinic.com/health/hepatitis-c/DS00097/METHOD=print. Accessed January 2010.
Ford, A. (2009 April). Singing new tunes for hepatitis testing. CAP Today Feature Story [On-line information]. Available online at http://www.cap.org/apps/portlets/contentViewer/show.do?printFriendly=true&contentReference=cap_today%2F0409%2F0409a_singing_new_tunes.html. Accessed January 2010.
Mukherjee, S. and Dhawan, V. (Updated 2009 June 18). Hepatitis C: Differential Diagnoses & Workup. eMedicine [On-line information]. Available online at http://emedicine.medscape.com/article/177792-diagnosis. Accessed January 2010.
Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 526-530.
Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 492-493.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 544-547.
(July 8, 2008) Centers for Disease Control and Prevention: Hepatitis C Information for Health Professionals. Available online at http://www.cdc.gov/hepatitis/HCV/index.htm. Accessed February 2010.
Davis GL, et al. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology. 2010 Feb;138(2): 513-521.
Sinnema, J. University of Alberta researchers move closer to hepatitis C vaccine. Postmedia News. February 15, 2012. Available online at http://www.canada.com/health/University+Alberta+researchers+move+closer+hepatitis+vaccine/6159502/story.html?id=6159502. Accessed February 2012.
Centers for Disease Control and Prevention. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965. Prepared by Smith, Bryce D. et al. MMWR. August 17, 2012. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm?s_cid=rr6104a1_w. Accessed August 2012.
(October 14, 2015) Centers for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. Available online at http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#d3. Accessed December 2015.
(October 15, 2015) Centers for Disease Control and Prevention. Hepatitis C FAQs for the Public. Available online at http://www.cdc.gov/hepatitis/hcv/cfaq.htm#cFAQ61. Accessed December 2015.
(© 2009) Ghany M, et al. Diagnosis, Management and Treatment of Hepatitis C, An Update. Hepatology, the American Association for the Study of Liver Diseases Practice Guidelines. Available online through http://www.aasld.org. Accessed July 2013.
(May 10, 2013) Centers for Disease Control and Prevention. Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. MMWR May 10, 2013 / 62(18);362-365. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6218a5.htm. Accessed June 2013.
(2013) Centers for Disease Control and Prevention. Interpretation of Results of Tests for Hepatitis C Virus (HCV) Infection and Further Actions. PDF available for download at http://www.cdc.gov/hepatitis/HCV/PDFs/hcv_graph.pdf. Accessed June 2013.
(1999) U.S. Food and Drug Administration. Device Approvals and Clearances. Home Access Hepatitis C Checksm and Hepatitis C Checksm Express. Available online at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=P980046. Accessed June 2013.
Fischbach, F.T. (2004). A Manual of Laboratory & Diagnostic Tests. 7th Edition., Lippincott Williams & Wilkins, Philadelphia.
(July 8, 2008) Centers for Disease Control and Prevention. Hepatitis C Information for Professionals. Available online at http://www.cdc.gov/hepatitis/HCV/index.htm. Accessed July 2013.
(July 21, 2008) Centers for Disease Control and Prevention. Hepatitis C FAQs for Professionals. Available online at http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed July 2013.
(May 10, 2013) Centers for Disease Control and Prevention. Vital Signs: Evaluation of Hepatitis C Virus Infection Testing and Reporting — Eight U.S. Sites, 2005–2011. MMWR 62(18);357-361. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm62e0507a1.htm?s_cid=mm62e0507a1_w. Accessed May 14, 2013.
Ly K, et al. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. Ann Intern Med, February 21, 2012 vol. 156 no. 4 271-278. Available online http://www.annals.org/content/156/4/271.full through http://www.annals.org. Accessed July 2013.
Rein D, et al. The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings. Ann Intern Med, February 21, 2012, vol. 156 no. 4, 263-269. Available online at http://www.annals.org/content/156/4/263-270. Accessed July 2013.
Alter HJ, Liang TJ. Hepatitis C. The End of the Beginning and Possibly the Beginning of the End. Ann Intern Med, February 21, 2012, vol 156 no. 4, 317-318. Available online at http://www.annals.org/content/156/4/317. Accessed July 2013.
Makiko Kitamura (Mar 14, 2012). Former Merck Unit Works on First Vaccine for Hepatitis C. Bloomberg. Available online at http://www.bloomberg.com/news/2012-03-14/former-merck-unit-works-on-first-vaccine-for-hepatitis-c.html. Accessed July 2013.
Centers for Disease Control and Prevention. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965. Prepared by Smith, Bryce D. et al. MMWR. August 17, 2012. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm?s_cid=rr6104a1_w. Accessed July 2013.